Literature DB >> 25294014

The relationship between circulating TRAIL and endothelial dysfunction in subclinical hypothyroidism.

Guangda Xiang1, Ling Yue, Junxia Zhang, Lin Xiang, Jing Dong.   

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is associated with atherosclerosis. Subclinical hypothyroidism (sHT) is associated with the increased prevalence of atherosclerotic lesions and cardiovascular events. Therefore, we hypothesized that circulating TRAIL levels are associated with endothelial dysfunction in sHT patients. Two hundred and four patients with newly diagnosed sHT and 52 healthy subjects were recruited. Circulating TRAIL concentration was measured by an ELISA, and flow-mediated dilation (FMD) of brachial artery was measured using high-resolution ultrasound. The mean value of circulating TRAIL in newly diagnosed sHT patients was 67.2 pg/ml, which was lower than that in controls (78.5 pg/ml, p < 0.001). By dividing the distribution of FMD levels into quartiles, TRAIL levels were increased gradually with the increase of FMD levels (p < 0.001). Multivariate regression analysis demonstrated that serum TRAIL levels were independently associated with FMD (p = 0.007). By logistic regression analysis, the odds ratio for lower FMD levels was reduced by 12.1 % per 1 pg/ml increase in serum TRAIL concentration after adjustment for multivariate metabolic factors [OR (95 % CI); 0.879 (0.721-0.973)]. Circulating TRAIL level decreased in newly diagnosed sHT patients and is positively associated with endothelial function, suggesting that circulating TRAIL level may be a protective marker of endothelial function in sHT patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25294014     DOI: 10.1007/s12020-014-0443-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  36 in total

1.  Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage.

Authors:  S M Mariani; P H Krammer
Journal:  Eur J Immunol       Date:  1998-03       Impact factor: 5.532

2.  TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways.

Authors:  Paola Secchiero; Arianna Gonelli; Edvige Carnevale; Daniela Milani; Assunta Pandolfi; Davide Zella; Giorgio Zauli
Journal:  Circulation       Date:  2003-03-31       Impact factor: 29.690

Review 3.  Endothelial dysfunction: a marker of atherosclerotic risk.

Authors:  Piero O Bonetti; Lilach O Lerman; Amir Lerman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-02-01       Impact factor: 8.311

4.  Evaluation of the effect of L-thyroxin therapy on endothelial functions in patients with subclinical hypothyroidism.

Authors:  Fatma Alibaz Oner; Selen Yurdakul; Ender Oner; Ayse Kubat Uzum; Mecdi Erguney
Journal:  Endocrine       Date:  2011-04-20       Impact factor: 3.633

5.  Postprandial lipaemia suppresses endothelium-dependent arterial dilation in patients with hypothyroidism.

Authors:  Guang Da Xiang; Ling Wei Xiang; Hong Lin He; Lin Shuang Zhao
Journal:  Endocrine       Date:  2012-02-22       Impact factor: 3.633

6.  Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes.

Authors:  Giorgio Zauli; Barbara Toffoli; Maria Grazia di Iasio; Claudio Celeghini; Bruno Fabris; Paola Secchiero
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

7.  C-Reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway.

Authors:  Paola Secchiero; Erika Rimondi; Maria Grazia di Iasio; Chiara Agnoletto; Elisabetta Melloni; Ilaria Volpi; Giorgio Zauli
Journal:  Clin Cancer Res       Date:  2013-03-06       Impact factor: 12.531

8.  Activated protein C decreases tumor necrosis factor related apoptosis-inducing ligand by an EPCR- independent mechanism involving Egr-1/Erk-1/2 activation.

Authors:  Lee A O'Brien; Mark A Richardson; Sean F Mehrbod; David T Berg; Bruce Gerlitz; Akanksha Gupta; Brian W Grinnell
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-11       Impact factor: 8.311

9.  TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice.

Authors:  Victoria Watt; Janet Chamberlain; Tanja Steiner; Sheila Francis; David Crossman
Journal:  Atherosclerosis       Date:  2011-01-28       Impact factor: 5.162

10.  Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction.

Authors:  Paola Secchiero; Federica Corallini; Claudio Ceconi; Giovanni Parrinello; Stefano Volpato; Roberto Ferrari; Giorgio Zauli
Journal:  PLoS One       Date:  2009-02-16       Impact factor: 3.240

View more
  4 in total

1.  Decreased serum TRAIL is associated with increased mortality in smokers with comorbid emphysema and coronary artery disease.

Authors:  Oluremi Ajala; Yingze Zhang; Aman Gupta; Jessica Bon; Frank Sciurba; Divay Chandra
Journal:  Respir Med       Date:  2018-10-19       Impact factor: 3.415

2.  Long non-coding RNA NEAT1 regulates endothelial functions in subclinical hypothyroidism through miR-126/TRAF7 pathway.

Authors:  Li Wang; Jingzhi Liu; Kunna Lu; Yuyu Qiu; Xiaoxia Li; Feng Yue; Xinhuan Zhang
Journal:  Hum Cell       Date:  2021-03-07       Impact factor: 4.174

3.  Autosomal Dominant Polycystic Disease is Associated with Depressed Levels of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand.

Authors:  Funda Sarı; Arzu Didem Yalçın; Gizem Esra Genç; Metin Sarıkaya; Atıl Bisgin; Ramazan Çetinkaya; Saadet Gümüşlü
Journal:  Balkan Med J       Date:  2016-09-01       Impact factor: 2.021

4.  The Association of Subclinical Hypothyroidism and Pattern of Circulating Endothelial-Derived Microparticles Among Chronic Heart Failure Patients.

Authors:  Alexander E Berezin; Alexander A Kremzer; Yulia V Martovitskaya; Tatyana A Samura; Tatyana A Berezina
Journal:  Res Cardiovasc Med       Date:  2015-09-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.